Based on initial topline data, IVERIC bio’s (NASDAQ:ISEE) Zimura met its prespecified primary endpoint in a Phase 2b dry age-related macular degeneration (AMD) clinical trial.
IVERIC’s Phase 2b trial assessed Zumira, a complement factor C5 inhibitor designed to reduce the rate of retinal tissue degeneration, in 286 dry AMD patients.
Patients treated with 2 mg and 4 mg of Zimura demonstrated a 27% and 28% reduction, respectively, in the mean rate of geographic atrophy (GA) growth over 12 months, compared to the sham control group. The company noted that these data are statistically significant and suggest a dose response relationship.
“This is a major milestone for IVERIC bio and a potentially significant advancement for patients with GA secondary to dry AMD who currently have no treatment options,” president and CEO Glenn Sblendorio said in a statement.
“Based on these data, we intend to explore all options for the future development of Zimura, including the possibility for collaboration opportunities, licensing and / or potentially further internal development,” he added.
